A new scientific paper drawn up by experts on behalf of the EU public-private Trials@Home project discusses the pros and cons of various terms being used to refer to decentralized clinical trials and suggests a unified way forward.
While there is a growing interest in the adoption of decentralized elements in clinical trials, in which activities are centered around study participants rather than investigator sites, the lack of standardized terminology for such research can hamper meaningful discussions on this front.
A new paper, published in the scientific journal Drug Discovery Today, proposes doing away with terms like “remote” or “virtual” trials when referring to a decentralized trial (DCT), which...
Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
